Palatin Technologies ($PTN) closes deal with Amagen

Palatin Technologies Inc. ($PTN) recently announced the closing of its licensing agreement with Amagen Pharmaceuticals, Inc. ($AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide). The drug is an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The licensing agreement [...]

By |February 3rd, 2017|Opinions|0 Comments

Mylan NV ($MYL) reports antitrust investigation

Mylan NV ($MYL) announced that it is being investigating by the US antitrust authorities for its EpiPen emergency allergy treatment. The company was earlier asked for information by the Federal Trade Commission as part of a preliminary investigation. The company had been severely criticized for raising the price of a [...]

By |February 2nd, 2017|Opinions|0 Comments

Ophthotech Corp ($OPHT) appoints new CFO and COO

Ophthotech Corp ($OPHT) reported it is looking at strategic alternatives for maximizing returns to its shareholders. The main focus of the plan will be on obtaining rights to additional products, product candidates and technologies to treat ophthalmic diseases, particularly those of the back of the eye. As part of the [...]

By |February 1st, 2017|Opinions|0 Comments

Sanofi ($SNY) gets sued for insulin price increase

Drug companies have come under fire for exorbitant increase in their drug prices. A lawsuit, filed on Monday in a federal court in Massachusetts, has named Sanofi SA ($SNY), Novo Nordisk ($NVO) and Eli Lilly and Co ($LLY). The case pertains to price fixing as it claimed that the companies [...]

By |January 31st, 2017|Opinions|0 Comments

Emergent BioSolutions ($EBS) get approval for new construction site in Germany

Emergent BioSolutions ($EBS) announced receiving approval from German Federal Ministry of Health for the construction of Building 55. The building will be used for manufacturing BioThrax. The approval will also allow the company to market the drug in Germany. Currently, BioThrax is the only anthrax vaccine licensed by the Paul-Ehrlich-Institut [...]

By |January 30th, 2017|Opinions|0 Comments

Eli Lilly ($LLY) cancels long running collaboration with Adocia

Eli Lilly and Co ($LLY) announced that it has terminated its collaboration with Adocia. The firms had inked the deal in December, 2014 with the intent of developing BioChaperone Lispro, an ultra-rapid insulin, for the treatment of type 1 and type 2 diabetes. Eli Lilly sent a letter to Adocia, [...]

By |January 27th, 2017|Opinions|0 Comments

Endo International ($ENDP) cuts 90 Jobs

Endo International ($ENDP) announced restructuring it business as it plans to cut down 90 full time jobs, in order to cut costs of operations. The step is likely to result in saving of $40 million to $50 million a year. The company is believed to have 6,400 employees on its [...]

By |January 26th, 2017|Opinions|0 Comments

Pacira Pharmaceuticals ($PCRX) announces new collaboration with DePuy Sythes Sales

Pacira Pharmaceuticals ($PCRX) announced that it has inked a new deal with DePuy Sythes Sales. The new deal is aimed at promoting the use of EXPAREL (bupivacaine liposome injectable suspension) for orthopedic procedures in the U.S. The company products are mainly geared towards managing opioid abuse. The company chairman and [...]

By |January 25th, 2017|Opinions|0 Comments

Cytori Therapeutics ($CYTX) acquires assets of Azaya Therapeutics

Cytori Therapeutics ($CYTX) announced the acquisition of certain assets from Azaya Therapeutics, which is a privately held firm. Under the terms of the deal, Cytori will issue $2 million in Cytori common stock up front. It will also assume nearly $2 million of Azaya’s trade payables. The overall value of [...]

By |January 24th, 2017|Opinions|0 Comments

AbbVie Inc. ($ABBV) increases Humira prices, receives FDA approval for new drug

Pharmaceutical sector is in bind as the new Donald Trump administration begins to start functioning. The new president has eluded that the drug companies may see lots of changes coming their way. One big area of concern is the drug pricing. Regardless of the political scenario, AbbVie company has announced [...]

By |January 23rd, 2017|Opinions|0 Comments

A quick look at Recro Pharma $REPH

Recro Pharma develops non-opioid drugs for pain management. REPH is targeting an NDA this year for its fast-acting IV version of Meloxicam, a well-known NSAID whose oral version just takes too long to work, but has been shown to be effective. REPH is even developing an intramuscular delivery format for [...]

By |January 22nd, 2017|Opinions|0 Comments

Abbott Laboratories ($ABT) continues the launch of new products, stock rises

Abbott Laboratories ($ABT) announced that it has launched its Proclaim DRG Neurostimulation System in Europe. The system is designed to deliver dorsal root ganglion stimulation to patients with chronic neuropathic pain. The system is magnetic resonance conditional. It is also recharge free and is easy to use as it uses [...]

By |January 20th, 2017|Opinions|0 Comments

Celsion ($CLSN) receives two new patents for ThermoDox

Celsion Corporation ($CLSN) reported receiving two new patents for ThermoDox formulation. The company said that one patent has been granted by the United States Patent and Trademark Office, while the other comes from Korea. These patents will help boosting the global coverage of ThermoDox, which is currently in Phase III [...]

By |January 19th, 2017|Opinions|0 Comments

Forward Pharma settles the case with Biogen

Forward Pharma A/S ($FWP) announced that it has signed a Settlement and License Agreement with Biogen ($BIIB). Both the companies were engaged in a dispute over a patent covering methods of treating multiple sclerosis (MS) with 480 mg of dimethyl fumarate (DMF), the active ingredient in Biogen's top selling Tecfidera. [...]

By |January 18th, 2017|Opinions|0 Comments

Herbalife ($HLF) starts the year with renewed upswing

Herbalife ($HLF) stock shows strong movements in its Friday trading sessions. The stock recorded intraday high of $52.20, before closing at $52, up 4.12%. The company stock reacted to the news of the resignation by Federal Trade Commission Chairwoman Edith Ramirez. She had been a vocal opponent of the company’s [...]

By |January 17th, 2017|Opinions|0 Comments

Mast Therapeutics Surges on Merger with Savara

Mast Therapeutics Inc. ($MSTX) stock gained over 57% this year so far as the company announced its merger with specialty Pharmaceuticals company Savara Inc. The gain this year has helped the stock in recouping some of the losses it had incurred in the previous year. Pursuant to the merger, the [...]

By |January 16th, 2017|Opinions|0 Comments

Illumina ($ILMN) provides strong forecast, stock upbeat

Illumina Inc. ($ILMN) has shown encouraging stock price movement in the new year. Its stock is 27% up on year to date basis, thanks to positive news from the company. Illumina recently announced the launch of a new DNA sequencer with new architecture. The company said that the new architecture [...]

By |January 13th, 2017|Opinions|0 Comments

MiMedx Group announces fourth quarter results, provides guidance

MiMedx Group ($MDXG) reported upbeat results for its fourth quarter recently. The company also provided encouraging forecast for FY 2017. Its fourth quarter revenue surged 38 percent to touch $71.6 million figure. The total revenue for the FY 2016 stood at $246.8 million, up 32% on year over year basis. [...]

By |January 12th, 2017|Opinions|0 Comments

Merck announces collaboration with Eli Lilly for immune-oncology treatments

Merck ($MRK) has expanded the scope of its immune-oncology tie up with Eli Lilly ($LLY). The alliance has started a new study for assessing the combination of LARTRUVO (olaratumab) and KEYTRUDA (pembrolizumab) in treatment-experienced patients with advanced/metastatic soft tissue sarcoma (STS). LARTRUVO was approved by the FDA in October 2016, [...]

By |January 11th, 2017|Opinions|0 Comments

Merrimack Pharmaceuticals ($MACK) to divest some assets

Merrimack Pharmaceuticals ($MACK) announced selling some of its assets to Ipsen ($IPSEY). These assets include pancreatic cancer drug Onivyde. The deal is likely to be valued at nearly $1 billion. Ipsen will pay $575 million at the closing of the deal. It will also pay up to $450 million upon [...]

By |January 10th, 2017|Opinions|0 Comments
s2Member®